Lopinavir/ritonavir (drug) — Competitive Intelligence Brief

Lopinavir/ritonavir (drug) (Lopinavir/ritonavir (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor combination. Area: Infectious Disease.

phase 3 HIV protease inhibitor combination HIV protease Infectious Disease Small molecule

Target snapshot

Lopinavir/ritonavir (drug) (Lopinavir/ritonavir (drug)) — Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba. Lopinavir/ritonavir is a combination protease inhibitor that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopinavir/ritonavir (drug) TARGET	Lopinavir/ritonavir (drug)	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba	phase 3	HIV protease inhibitor combination	HIV protease
Darunavir ritonavir	Darunavir ritonavir	St Stephens Aids Trust	marketed	HIV protease inhibitor (boosted)	HIV protease
Antiretroviral/Anti HIV	Antiretroviral/Anti HIV	MSD Pharmaceuticals LLC	marketed	Antiretroviral agent (multiple classes: NRTI, NNRTI, PI, INSTI, entry inhibitor)	HIV reverse transcriptase, HIV protease, HIV integrase, CCR5, or CXCR4 (depending on specific agent)
Darunavir, Ritonavir, Truvada	Darunavir, Ritonavir, Truvada	Imperial College London	marketed	Antiretroviral combination therapy (protease inhibitor + reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase, CYP3A4
Lopinavir/ritonavir and ritonavir	Lopinavir/ritonavir and ritonavir	University of Miami	marketed	HIV protease inhibitor	HIV protease
Reducing dose of Lopinavir	Reducing dose of Lopinavir	University Hospital, Geneva	marketed	HIV protease inhibitor	HIV protease
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	UPECLIN HC FM Botucatu Unesp	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor combination class)

1. Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba · 1 drug in this class
2. Ottawa Hospital Research Institute · 1 drug in this class
3. The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class
4. ViiV Healthcare · 1 drug in this class